ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors	Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), central nervous system cancer, central nervous system neoplasm, ependymoma, epithelial neoplasm, glioblastoma, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor, spinal cord glioma	Recruiting	Phase 1	2026-06-11		NCT04732065

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Dana-Farber Cancer Institute	324
Jazz Pharmaceuticals	60
Mithil Prasad Foundation	2
National Cancer Institute (NCI)	3015
Sabine Mueller, MD, PhD	7
Storm the Heavens Fund	2
The ChadTough Defeat DIPG Foundation	1

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Children's Hospital of Philadelphia	Philadelphia	United States	434
Children's National Hospital	Washington D.C.	United States	100
Emory University	Atlanta	United States	262
Princess Máxima Center for Pediatric Oncology	Utrecht	Netherlands	3
The University Children's Hospital in Zurich	Zurich	Switzerland	2
University of California, San Francisco	San Francisco	United States	294
University of Michigan	Ann Arbor	United States	538